Evidence map›Paper›PMID 31519924›Full record

ArticleScientific reports2019

Generation of c-MycER

Gerardo Santiago-Toledo, Melanie Georgiou, Joana Dos Reis, Victoria H Roberton, Ana Valinhas, Rachael C Wood, James B Phillips, Chris Mason, Daqing Li, Ying Li and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Immortalization Reversibility in the Context of Cell Therapy Biosafety.International journal of molecular sciences · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Gerardo Santiago-ToledoDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
Melanie GeorgiouDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
Joana Dos ReisDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
Victoria H RobertonDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.ORCID http://orcid.org/0000-0002-0404-6984
Ana ValinhasDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
Rachael C WoodDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
James B PhillipsDepartment of Pharmacology, UCL School of Pharmacy, London, WC1N 1AX, UK.ORCID http://orcid.org/0000-0001-8117-3074
Chris MasonDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK.
Daqing LiDepartment of Neurosurgery, National Hospital for Neurology & Neurosurgery, London, WC1N 3BG, UK.
Ying LiDepartment of Neurosurgery, National Hospital for Neurology & Neurosurgery, London, WC1N 3BG, UK.
John D SindenUCL Centre for Nerve Engineering, London, WC1E 6BT, UK.
David ChoiUCL Centre for Nerve Engineering, London, WC1E 6BT, UK.
Parmjit S JatMRC Prion Unit at UCL, Institute of Prion Diseases, London, W1W 7FF, UK.
Ivan B WallDepartment of Biochemical Engineering, University College London, London, WC1H 0AH, UK. i.wall@aston.ac.uk.
University College London · GBNerve Centre · GBAston University · GBNational Hospital for Neurology and Neurosurgery · GBAVEO Oncology (United States) · USMRC Prion Unit · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K011154/1Wellcome TrustWellcome Trust 200135/Z/15/Z
6 · The paper itself

Abstract

Human olfactory mucosa cells (hOMCs) have been transplanted to the damaged spinal cord both pre-clinically and clinically. To date mainly autologous cells have been tested. However, inter-patient variability in cell recovery and quality, and the fact that the neuroprotective olfactory ensheathing cell (OEC) subset is difficult to isolate, means an allogeneic hOMC therapy would be an attractive "off-the-shelf" alternative. The aim of this study was to generate a candidate cell line from late-adherent hOMCs, thought to contain the OEC subset. Primary late-adherent hOMCs were transduced with a c-MycER

Indexed as

Genes, mycAdultAnimalsBiomarkersCell LineCoculture TechniquesGanglia, SpinalGentamicinsHumansKaryotypingMiceNeuroblastomaOlfactory MucosaRatsRats, Sprague-DawleyReceptors, Estrogenafimoxifeneantibiotic G 418BiomarkersGentamicinsReceptors, EstrogenRecombinant ProteinsTamoxifen

Identifiers

PMID31519924
PMCPMC6744411
OpenAlexW2972455146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.